Tech Company Financing Transactions
Mineralys Therapeutics Funding Round
On 6/8/2022, Mineralys Therapeutics raised $118 million in Series B funding from Andera Partners, RA Capital and Adams Street Partners.
Transaction Overview
Company Name
Announced On
6/8/2022
Transaction Type
Venture Equity
Amount
$118,000,000
Round
Series B
Investors
Andera Partners (Lead Investor) (Olivier Litzka)
RA Capital (Lead Investor) (Derek DiRocco)
Proceeds Purpose
Mineralys plans to use the proceeds to continue to advance MLS-101, a highly selective aldosterone synthase inhibitor. MLS-101 is currently being evaluated in a Phase 2 clinical trial, called Target-HTN, for patients with uncontrolled hypertension. The Company anticipates releasing the top-line results of Target-HTN later this year.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
150 N. Radnor Chester Rd. F200
Radnor, PA 19087
USA
Radnor, PA 19087
USA
Phone
Website
Email Address
Overview
Mineralys Therapeutics is a private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension. We are driven to bring a targeted approach to the management of hypertension.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
BT Slingsby
Chief Executive Officer
Jon Congleton
Chief Financial Officer
Adam Levy
Chief Medical Officer
David Rodman
VP - Operations
Jessica Ibbitson
Browse more venture capital transactions:
Prev: 6/8/2022: Front Financial venture capital transaction
Next: 6/8/2022: Nava Benefits venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs